| Proposed issue of securities - NXN | Nov 20, 2026 | Financing | ASX |
|---|
| Nexsen Appointments to Advisory Board | Nov 15, 2026 | Other filings | ASX |
|---|
| A$1.2 million R&D Tax Incentive refund received | Nov 12, 2026 | Results | ASX |
|---|
| Results of Meeting | Nov 9, 2026 | Meeting outcome | ASX |
|---|
| Nexsen advances kidney diagnostics program | Nov 5, 2026 | Other filings | ASX |
|---|
| Co Secretary Appoint/Resign and Change of Registered Address | Nov 2, 2026 | Other filings | ASX |
|---|
| ISO 13485 Certification brings StrepSure closer to market | Nov 1, 2026 | Operations update | ASX |
|---|
| Quarterly Report - Q1 FY27 | Oct 27, 2026 | Quarterly report | ASX |
|---|
| Quarterly Report - Q1 FY27 | Oct 27, 2026 | Quarterly report | ASX |
|---|
| Notice of AGM and Meeting Materials | Oct 7, 2026 | Meeting notice | ASX |
|---|
| Professor Shekhar Kumta appointed Executive Director | Sep 30, 2026 | Management or board change | ASX |
|---|
| Reinstatement to Quotation | Sep 24, 2026 | Trading halt or suspension | ASX |
|---|
| Proposed FlashDx joint venture builds on CE-marked GBS test | Sep 24, 2026 | Operations update | ASX |
|---|
| Suspension from Quotation | Sep 23, 2026 | Trading halt or suspension | ASX |
|---|
| Clear pathway defined to optimise StrepSure | Sep 23, 2026 | Operations update | ASX |
|---|
| Trading Halt | Sep 21, 2026 | Trading halt or suspension | ASX |
|---|
| Director Interest Notices re Performance Rights | Sep 10, 2026 | Ownership change notice | ASX |
|---|
| Notification regarding unquoted securities - NXN | Sep 10, 2026 | Other filings | ASX |
|---|
| Notification regarding unquoted securities - NXN | Sep 10, 2026 | Other filings | ASX |
|---|
| Annual Report - FY 2026 | Aug 30, 2026 | Annual report | ASX |
|---|
| Corporate Governance Statement and Appendix 4G | Aug 30, 2026 | Other filings | ASX |
|---|
| Quarterly Report - Q4 FY26 | Jul 28, 2026 | Quarterly report | ASX |
|---|
| $1.5m non-dilutive ARC funding for manufacturing | Jun 24, 2026 | Financing | ASX |
|---|
| Nexsen secures first hospital partner in Asia | May 12, 2026 | Operations update | ASX |
|---|
| Nexsen and Universiti Malaya launch joint facility | May 3, 2026 | Operations update | ASX |
|---|
| Quarterly Report - Q3 FY26 | Apr 27, 2026 | Quarterly report | ASX |
|---|
| QMS milestone achieved | Apr 6, 2026 | Operations update | ASX |
|---|
| HK$6 million grant awarded to advance Asia-Pacific execution | Mar 30, 2026 | Operations update | ASX |
|---|
| Nexsen accelerates global rollout for StrepSure | Mar 25, 2026 | Operations update | ASX |
|---|
| FDA feedback derisks US approval pathway for StrepSure | Mar 22, 2026 | Operations update | ASX |
|---|
| Half Yearly Report and Accounts | Feb 26, 2026 | Interim report | ASX |
|---|
| Quarterly Report - Q2 FY26 | Jan 29, 2026 | Quarterly report | ASX |
|---|
| $500k govt grant expands GBS project to neonates | Jan 26, 2026 | Operations update | ASX |
|---|
| Investor Presentation | Dec 7, 2025 | Other filings | ASX |
|---|
| Nexsen Appoints Global Clinical Leader to the Board | Dec 2, 2025 | Management or board change | ASX |
|---|
| Quarterly Report - Q1 FY26 | Oct 31, 2025 | Quarterly report | ASX |
|---|
| Nexsen launches clinical trial for GBS Rapid Sensor | Oct 20, 2025 | Operations update | ASX |
|---|